Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01633372 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01633372 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 87 participants.
The verdict
NCT01633372, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
Interventions
- DRUG itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-07-16 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01633372
The ClinicalTrials.gov registry entry for NCT01633372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which itacitinib is the first listed.
NCT01633372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01633372 about?
NCT01633372 is a clinical study titled "An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis". This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
What is the current status of trial NCT01633372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2012-07-16. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT01633372?
The interventions under investigation include: itacitinib (DRUG).
Who is sponsoring clinical trial NCT01633372?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.